CONTACT:
Rachel Bloom
Zeneca Pharmaceuticals
302-886-7858
[email protected]
FOR IMMEDIATE RELEASE
ZENECA PHARMACEUTICALS INTRODUCES EDUCATIONAL AND INFORMATIONAL WEBSITE FOR ANESTHESIOLOGY AND CRITICAL CARE PROFESSIONALS
WILMINGTON, Del. - January 5, 1998 - Health care professionals involved in the administration of general anesthesia, sedation of patients in the intensive care unit (ICU), and monitored anesthesia care (MAC) can now visit a new World Wide Web site containing frequently updated information and educational programs. Future plans include additional programs which offer continuing medical education credits.
The Website, located at http://www.diprivan.com, was created by Zeneca Pharmaceuticals. The Company introduced the Website recently at the annual meeting of the American Society of Anesthesiology.
The site will house a number of informational and educational modules. Presently, five modules are available.
-- Module I: Administration of DIPRIVAN (R) (propofol) Injectable Emulsion for MAC and for sedation in the ICU
-- Module II: DIPRIVAN Professional Information Brochure
-- Module III: Pharmacoeconomics (will include continuing education credits CEU in the future)
-- Module IV: Search section
-- Module V: Feedback section
"We are very excited about this use of the Internet as a medium for information and educational programs exclusively for health care professionals involved in anesthesia and critical care," said Zahir A. Ladhani, Group Product Manager, Hospital Care Marketing. "Zeneca will continue to explore interesting and creative avenues to offer professional education programs as part of our ongoing commitment to provide pharmaceutical products that meet the highest standards of safety and effectiveness."
New modules will be added regularly. For example, visitors to the site in the near future will be able to explore important aspects of medical information for anesthesia professionals and pharmacists. Components of this module will include board reviews, monographs, and a slide lecture series. Plans for additional interactive contents for the site include modules focused on current issues in ICU sedation, current issues in anesthesia, and common clinical questions.
DIPRIVAN is the first of a new class of intravenous drugs which can be used for both induction and maintenance of general anesthesia. Since its introduction in 1989, DIPRIVAN has been administered to more than 190 million patients worldwide and is considered a valuable advance in the anesthetic drug armamentarium.
Zeneca Inc. is a $3.1 billion bioscience business with approximately 7,200 employees in the US. Zeneca Inc. is a wholly-owned subsidiary of the UK-based Zeneca Group PLC (NYSE:ZEN), a major $9 billion international bioscience business engaged in the research, development, manufacture, and marketing of ethical (prescription) pharmaceuticals, agricultural and specialty chemical products, and the supply of health care services.
# # #
NOTE: For full prescribing information for DIPRIVAN, please call Rachel Bloom at 302-886-7858 or access the World Wide Web at http://www.diprivan.com.
RSS